8-K: Option Care Health Q1 2026 Results Mixed, Guidance Adjusted

Option Care Health reported mixed first quarter 2026 financial results, with revenue up slightly but Adjusted EBITDA down, leading to an adjustment in full-year revenue guidance.

Summary

• Option Care Health announced its first quarter 2026 financial results, reporting net revenue of $1,350.7 million, a 1.3% increase year-over-year.
• GAAP Net income was $45.3 million, a decrease of 3.0%, and GAAP diluted earnings per share was $0.29, up 3.6%.
• Adjusted EBITDA decreased by 6.3% to $104.8 million, while Adjusted diluted earnings per share remained flat at $0.40.
• The company used $12.1 million in operating activities during the quarter and repurchased $17.5 million of its stock.
• The revolving credit facility was expanded from $400 million to $850 million.
• Full-year 2026 guidance for net revenue has been adjusted to $5.675 billion to $5.775 billion, while Adjusted EBITDA and Adjusted diluted EPS guidance remain unchanged.
• The company is implementing actions to re-accelerate revenue growth.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious sentiment due to mixed financial results, a decline in Adjusted EBITDA, and a CEO statement expressing dissatisfaction with revenue growth momentum, despite stable Adjusted EPS and an expanded credit facility.

Positives

• Net revenue increased by 1.3% to $1,350.7 million.
• GAAP diluted earnings per share increased by 3.6% to $0.29.
• Adjusted diluted earnings per share remained flat at $0.40, with a $0.02 year-over-year benefit from share repurchases.
• The revolving credit facility was significantly expanded from $400 million to $850 million.
• The company expects to generate at least $320 million in cash provided by operating activities for the full year 2026.
• Strong execution was noted across the Acute business segment.

Negatives

• GAAP Net income decreased by 3.0% to $45.3 million.
• Adjusted EBITDA decreased by 6.3% to $104.8 million.
• Cash used in operating activities was $12.1 million for the quarter.
• Revenue growth momentum is not satisfactory, according to the CEO.
• A significant headwind from the Chronic Inflammatory Disease (CID) portfolio is impacting revenue and gross profit.

Risks

• Changes in laws, regulations, or trade policies applicable to the business model.
• Loss of relationships with managed care organizations and other non-governmental third-party payers.
• Changes in the pharmaceutical industry, including limitations or discontinuations in research, development, production, and marketing of compatible pharmaceuticals.
• Changes in market conditions and receptivity to services and offerings.
• Pending and future litigation or potential liability for claims not covered by insurance.

Future Outlook

For the full year 2026, Option Care Health now expects net revenue between $5.675 billion and $5.775 billion, Adjusted diluted earnings per share between $1.82 and $1.92, and Adjusted EBITDA between $480 million and $505 million. The company also anticipates at least $320 million in cash provided by operating activities.

Management Comments

• "The first quarter reflected a mixed performance for our business, and we are not satisfied with our revenue growth momentum."
• "Our team continues to provide high-quality care for patients and deepen relationships with key stakeholders and our foundation remains strong."
• "We are an execution-driven organization and are taking decisive actions to re-accelerate our growth trajectory and position us for greater long-term value creation."

Industry Context

StockSavvy.ai notes that Option Care Health's Q1 2026 results highlight challenges within the chronic infusion services segment, particularly the Chronic Inflammatory Disease (CID) portfolio, which is impacting overall revenue and gross profit. This contrasts with strong performance in the Acute segment, suggesting a bifurcated market dynamic within the home and alternate site infusion services sector.

Stakeholder Impact

• Shareholders may be concerned by the decline in Adjusted EBITDA and the CEO's dissatisfaction with revenue growth, potentially impacting stock price.
• Customers and patients may experience continued high-quality care, as stated by management, but future growth initiatives could impact service delivery.
• Suppliers may be affected by revenue pressures and the company's focus on cost management and strategic initiatives.

Next Steps

• Implement decisive actions to re-accelerate revenue growth trajectory.
• Drive greater long-term value creation.
• Continue focus on strategic initiatives.
• Host conference call to discuss results on April 30, 2026.

Key Dates

Recommendation

The company shows stable adjusted EPS and an expanded credit facility, but the decline in Adjusted EBITDA, unsatisfactory revenue growth, and a CEO comment expressing concern warrant a cautious approach. The company's stated actions to re-accelerate growth and updated guidance need to be monitored for effectiveness before considering a stronger recommendation.

Keywords

Option Care Health, Infusion Services, Home Infusion, Alternate Site Infusion, Q1 2026 Results, Financial Results, Healthcare Provider, SEC Filing